Accellix Overview
Accellix's mission is to provide quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use on the manufacturing floor and at the point of care. The Accellix platform enables its partners in the field of cell therapy to meet their critical quality control requirements as they advance life-changing therapies benefiting patients worldwide.
Cumulative Funding Raised Over Time ($)
$1.6MApr 2012
$1.9MAug 2010
$1.9MJul 2009
$2.0MJun 2010
$9.0MJun 2014
$18.5MJun 2020
$18.8MSep 2009
Latest News
Accellix Expands its Leadership Team
Accellix, the Cell Therapy QC Company Raises $9.5 Million Series D Round
Accellix, Inc. Announces Their Next Generation Accellix Instrument and Consumable to Further Simplify and Automate the QC Workflow in Cell Therapy Manufacturing
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.73M |
| Last funding | $9.5M |
| Stage | D |
| Rounds | 7 |
| Investors | 3 |
Team Members
3
Employees: 51-200
Web & Social Links
| Website | www.accellix.com |
Locations
Shlomo Momo Ha'levi 5, Jerusalem, Israel
2385 Bering Drive, San Jose, CA, USA
Photos & Videos
1 item(s)
Accellix Business
Business models
B2B
Product stage
Clinical Trial
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesTarget Customer
ConsumersDemographics & FamilyBabiesHealthcare & Life SciencesHealthcareProvidersLaboratoriesCore Technology
Platforms & InterfacesSoftwareTags (14)
medical-technologieshospitalsreal-timemedical-deviceslaboratoriescritical-careblood-testbiomarkersdiagnosticsoperating-roomsdata-analyticssoftware-developmentdoctorsimmunotherapyGeographic Markets
EuropeAccellix Financials
$18.73M
Total funding
Undisclosed
Capital raised
$9.5M
Last funding
D
Funding stage
7
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$1.6MApr 2012
$1.9MAug 2010
$1.9MJul 2009
$2.0MJun 2010
$9.0MJun 2014
$18.5MJun 2020
$18.8MSep 2009
Private Equity Funding
D Round
Jun 2020
$9.5M
Undisclosed Investor(s), bioMrieux,
B Round
Jun 2014
$7M
Axcel Partners
Undisclosed Round
Apr 2012
$1.6M
Undisclosed Round
Aug 2010
$250K
Debt Financing
Jun 2010
$115K
Undisclosed Round
Sep 2009
$377K
Seed
Jul 2009
Undisclosed
Accellix Lifecycle
Cumulative Funding Raised Over Time
$1.6MApr 2012
$1.9MAug 2010
$1.9MJul 2009
$2.0MJun 2010
$9.0MJun 2014
$18.5MJun 2020
$18.8MSep 2009
All Events
D Round
Jun 2020
$9.5M
Undisclosed Investor(s), bioMrieux,
B Round
Jun 2014
$7M
Axcel Partners
Undisclosed Round
Apr 2012
$1.6M
Undisclosed Round
Aug 2010
$250K
Debt Financing
Jun 2010
$115K
Undisclosed Round
Sep 2009
$377K
Seed
Jul 2009
Undisclosed
Accellix News
11 articlesAccellix Expands its Leadership Team
Accellix, the Cell Therapy QC Company Raises $9.5 Million Series D Round
Accellix, Inc. Announces Their Next Generation Accellix Instrument and Consumable to Further Simplify and Automate the QC Workflow in Cell Therapy Manufacturing
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
growth-positive
Orgenesis Announces Co-Development Agreement with Accellix
Orgenesis Inc. has entered into a co-development agreement with Accellix, Inc. to integrate Accellixs proprietary optic system, cartridges, reagents, and software into Orgenesis Point of Care cellular therapy processing services and platform. The integration aims to advance Orgenesis quality control systems. The financial details of the agreement were not disclosed. Orgenesis POCare platform is designed to collect, process, and supply cells within the patient care location for therapeutic treatments. The Accellix assay delivery platform enhances the quality control aspects of Orgenesis POCare platform. The partnership is expected to lower costs and bring autologous therapies to patients in a cost-effective, high-quality, and scalable manner.
Partners
Accellix, Inc Expands Leadership Team and Announces Name Change
growth-positive
Emosis and Accellix Announce Intent to Form a Joint Venture, EmoCellix
Emosis and Accellix have signed a letter of intent to form a joint venture called EmoCellix. The joint venture will focus on marketing a complete solution for hemostasis cytomolecular diagnostics. EmoCellix will integrate Emosis novel hemostasis cytomolecular diagnostic tests with Accellixs innovative assay delivery platform. The joint venture aims to provide a complete solution for on-demand point-of-care hemostasis and thrombosis diagnostics. Emosis and Accellix will each own 50% of the joint venture. Customers will still have the option to purchase non-integrated products and services from both companies.
Partners
Unknown
http://www.marketwired.com/press-release/leukodx-ge-healthcare-enter-agreement-explore-solutions-cell-characterization-cell-therapy-2106534.htm
The article does not provide any information about a specific company or event.
growth-positive
LeukoDx Inc. Closes $7M Financing Round;Appoints Seymour Liebman & Mark Chess to BOD
LeukoDx Inc. has secured $7 million in new financing from Axcel Partners and individual investors. The funding will be used to accelerate the companys plans to bring the Accellix platform and rapid sepsis test to market. LeukoDx has also appointed Mark Chess and Seymour Liebman to serve as members of the Board of Directors. The companys mission is to deliver cost-effective, highly sensitive, and actionable diagnostic information at the point of care through its automated IVD flow cytometry platform. The Accellix platform and the Accellix Rapid Sepsis test are the companys first applications.
Investment
growth-positive
LeukoDx Closes $1.6M Financing Tranche, Inks Agreements for up to $8M
LeukoDx has secured commitments of up to $8 million in investments to develop its point-of-care platform for delivering flow cytometry in vitro diagnostic results. The initial $1.6 million tranche has been closed, and the remaining investment will depend on reaching certain milestones within the next two years. The company is also developing an assay for CD64 neutrophil activation under a licensing deal with Trillium Diagnostics, which will allow for rapid clinical diagnosis in various patient settings. LeukoDx is seeking partnerships with biotechnology and IVD companies to expand the menu for its platform.
InvestmentPartners
Accellix Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 70 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Accellix Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514248251 |
| Crunchbase | leukodx, accelix |
| Phone | +97226744422 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-18T00:00:00.000Z |
| Created | 2014-07-06T00:00:00.000Z |